Analysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) PT at $4.75

Shares of Gossamer Bio, Inc. (NASDAQ:GOSSGet Free Report) have received a consensus rating of “Hold” from the six research firms that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.75.

A number of research firms recently commented on GOSS. Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of Gossamer Bio in a research note on Tuesday, December 19th. HC Wainwright raised their price objective on shares of Gossamer Bio from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, January 8th.

View Our Latest Research Report on Gossamer Bio

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GOSS. ARCH Venture Management LLC purchased a new stake in Gossamer Bio in the 3rd quarter worth approximately $6,709,000. Vanguard Group Inc. lifted its position in Gossamer Bio by 214.6% in the 3rd quarter. Vanguard Group Inc. now owns 11,268,328 shares of the company’s stock worth $9,384,000 after buying an additional 7,686,213 shares in the last quarter. Silverarc Capital Management LLC purchased a new stake in Gossamer Bio in the 3rd quarter worth approximately $5,105,000. Monashee Investment Management LLC purchased a new stake in Gossamer Bio in the 3rd quarter worth approximately $4,417,000. Finally, Armistice Capital LLC purchased a new stake in Gossamer Bio in the 3rd quarter worth approximately $4,127,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Trading Up 1.1 %

Shares of NASDAQ:GOSS opened at $0.88 on Tuesday. The stock has a market capitalization of $198.36 million, a price-to-earnings ratio of -0.50 and a beta of 1.57. Gossamer Bio has a 1-year low of $0.45 and a 1-year high of $2.53. The company has a debt-to-equity ratio of 1.91, a quick ratio of 8.07 and a current ratio of 8.07. The company has a 50 day moving average price of $0.91 and a 200 day moving average price of $0.87.

About Gossamer Bio

(Get Free Report

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Featured Stories

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.